Response to: "Comment on 'Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry'"

J Am Acad Dermatol. 2021 Sep;85(3):e173-e174. doi: 10.1016/j.jaad.2021.02.072. Epub 2021 Mar 4.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Dermatitis, Atopic* / drug therapy
  • Eczema*
  • Humans
  • Netherlands
  • Registries

Substances

  • Antibodies, Monoclonal, Humanized
  • dupilumab